NCT04447183View on ClinicalTrials.gov

The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

August 31, 2024

Study Completion Date

October 31, 2024

Conditions
Differentiated Thyroid Cancer
Interventions
DRUG

Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH)

rhTSH: 0.9 mg IM daily on two consecutive days;radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral

OTHER

radioactive iodine

radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY